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Summary Perioperative management of anticoagulants and antiplatelet agents is based on a
compromise between the risk of hemorrhage induced by maintaining (or substituting for) them
and the risk of thrombosis if they are discontinued. The hemorrhage risk in major spinal surgery
is clear (50—81% incidence of transfusion), and the incidence of postoperative symptomatic
spinal hematoma varies between 0.4% and 0.2% depending on whether low-molecular-weight
heparin (LMWH) is prescribed postoperatively. The French Health Authority, in 2008, published
guidelines on the management of patients treated with vitamin K antagonists. Treatment may
be stopped without preoperative replacement in certain cases of atrial ﬁbrillation or venous
thromboembolic disease; otherwise, preoperative replacement by curative dose unfractionated
heparin (UFH) or LMWH is recommended, with withdrawal early enough to avoid peroperative
bleeding. Postoperative care should take account of hemorrhagic risk following surgery. The
management of patients treated with antiplatelets is delicate, as maintenance is preferable
in most of the situations in which they are prescribed (bare or active stenting, or secondary
prevention of myocardial infarction, stroke or peripheral ischemia), although they are liable to
increase the risk of perioperative hemorrhage, especially when associated to antithrombotic
prophylaxis. If surgery cannot be performed under treatment continuation, the interruption
should be as short as possible. New guidelines are presently being drawn up under the auspices
of the French Health Authority. In both types of treatment, the strategy should be jointly
determined by surgeon, anesthesiologist and cardiologist, to optimize individualized care taking
account of each party’s requirem
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Introduction
Perioperative management of anticoagulants and
antiplatelet agents is a concern shared by anesthesi-
ology and surgery teams. The latter face the risk of
hemorrhage induced by an aggressive procedure and
enhanced by maintenance of treatment and by the risk of
arterial or venous thrombosis associated with perioperative
withdrawal. Spinal surgery covers a wide variety of proce-
dures, with varying associated hemorrhage risk precluding
any single solution. The considerations discussed in the
present article focus on these various aspects with a view to
recommending rational attitudes guided by the association
of surgical and patient-based risks.
Hemorrhage and thrombosis risk in spine
surgery
Hemorrhage risk
The hemorrhage risk speciﬁc to spinal surgery seems not to
be clearly assessed in the various attempted stratiﬁcations
of surgical specialties. Orthopedic and neurologic surgeries
are respectively classiﬁed as moderate and high risk, but
spine surgery is not given a classiﬁcation [1].
Hemorrhage risk depends partly of the degree of blood
loss, but also on the postoperative location of hemorrhage
(spinal hemorrhage).
Blood loss ranged from 650 to 2839mL in 900 patients
undergoing arthrodesis surgery without preventive strate-
gies for bleeding [2]; the transfusion rate ranged from 50% to
81%. Most cases involved instrumentation, recognized in pre-
vious studies as a factor of increased bleeding and need for
transfusion [3]. Postoperative hemorrhage in 2507 patients
undergoing spine surgery with antithrombotic prophylaxis
ranged from 0 to 4.3% depending on the study [4]. Four inde-
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Table 1 Prevention of deep venous thrombosis: French Anesthesio
Head, neck and spine surgery
Surgical risk Patient-related
Low
ENT −
Discal hernia
1 or 2 level cervical laminectomy +
Moderate
Extensive cervical laminectomy −
Dorsolumbar laminectomy
Spinal osteosynthesis +
High
Intracranial neurosurgery
Medullary trauma
LMWH: low-molecular-weight heparin; UFH: unfractionated heparin; GC
compression.S103
endent factors were identiﬁed as predictive of transfusion
n 230 patients undergoing scheduled thoracolumbar surgery
5]: age superior than 50 years, preoperative hemoglobin
oncentration inferior than 12 g/dL, superior than two levels
f arthrodesis, and transpedicular osteotomy. By weighting
ach of these factors, the authors were able to draw up
predictive score perfectly correlated with the number of
rythrocyte concentrates actually delivered.
Spinal hematoma is a major postoperative hemorrhagic
omplication. A meta-analysis of 493 articles published
etween 1966 and 2007 [6] found 16 studies identify-
ng risk of symptomatic hematoma with (n = 6) or without
n = 10) associated antithrombotic prophylaxis. Incidence
aried between 0.4% and 0.2% depending on whether low-
olecular-weight heparin (LMWH) was prescribed or not.
hese ﬁgures are very low compared to those for asymp-
omatic postoperative hematoma detected on MRI [7,8].
hese ﬁndings are comparable to those of Cheng et al.
4], who reported 10 hematomas in 2507 patients operated
n. This rate is comparable to that observed in anesthesio-
ogic practice providing epidural analgesia with concomitant
reatment affecting [9]. It clearly raises the problem of
dapted postoperative anticoagulant and antiplatelet man-
gement.
hrombosis risk
he 2005 French Anesthesiology and Intensive Care Soci-
ty (Société franc¸aise d’anesthésie réanimation [SFAR])
ecommendations for antithrombotic prophylaxis [10] in
pine surgery identify three risk categories, with preven-
ion strategies adapted to the surgical procedure and patient
tatus (Table 1).The 2008 American guidelines [11] recommend no pro-
hylaxis in moderate risk surgery, LMWH, unfractionated
eparin (UFH) or intermittent pneumatic compression (IPC)
n case of minor associated risk factors, and combined phar-
logy and Intensive Care Society (SFAR) 2005 recommendations.
risk Recommendations Grade
Nothing or GCS D
LMWH D
UFH±GCS D
LMWH±GCS D
IPC D
LMWH D
LMWH/UFH A/B
+GCS or IPC C
LMWH or UFH B
+GCS or IPC C
S: graduated compression stocking; IPC: intermittent pneumatic
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acologic and mechanical prophylaxis in case of major
hrombosis risk factors. In case of major postoperative hem-
rrhage risk (multiple trauma), priority should be given to
PC, with medical prophylaxis as a bridge or complement
uring phase-out.
The most recent reports argue for overall reduction of
ostoperative thrombosis risk [4]. In absence of prophylaxis,
he risk of documented (phlebography, Doppler, ultrasound
r ﬁbrinogen test) deep venous thrombosis (DVT) in a popu-
ation of 1,619 patients was 6% in trauma without medullary
nvolvement, 5.3% in deformity and 2.3% in degenerative
amage; risk of pulmonary embolism (PE) in the same indi-
ations was respectively 2%, 2.7% and 0.4%. Incidence of DVT
nd PE respectively ranged from 0 to 0.6% and 0 to 0.2% in
ase of antithrombotic prophylaxis. Another meta-analysis
12] reported overall prevalence of 1.09% for DVT and 0.06%
or PE (total of 4383 patients). In absence of prophylaxis,
ncidence of DVT was 5.8%. Operative level (cervical vs.
horacolumbar) and type of pathology did not impact DVT
revalence.
erioperative management of anticoagulants
nd antiplatelets
atients under vitamin K agonists (VKA)
itamin K agonists treatment is basically indicated in
atients equipped with a mechanical cardiac valve or sub-
ect to atrial ﬁbrillation or venous thromboembolic disease.
n 77% of cases, the drug prescribed in France is ﬂuindione
Préviscan®). The hemorrhage risk associated with surgery
epends on the international normalized ratio (INR), an
ndex of anticoagulant level. Target INR in most procedures
s inferior than 1.5; it should be inferior than 1.2 in neuro-
urgery, and likewise probably in spinal surgery involving a
isk of postoperative spinal hematoma. Table 2 shows throm-
osis risk associated with withdrawal of treatment.
Perioperative management of VKA was the subject of
he 2008 French Health Authority (Haute Autorité de la
anté [HAS]) recommendations [13]. In situations of moder-
te risk, treatment is withdrawn preoperatively (last dose,
-5), without bridging. In case of elevated thrombosis risk,
KAs are bridged by preoperative heparin (iv UFH to obtain
CT= 2—3× control; subcutaneous UFH, 400 IU/kg per two
njections; curative dose LMWH in two injections per day
n case of mechanical valves or AF). Iv UFH, subcutaneous
FH and LMWH are terminated respectively 4—6, 8—12 and
a
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Table 2 Thrombosis risk on termination of vitamin K agonists (VK
Mechanical valve AF
Moderate risk All
High risk Any mechanical valve S,
AF: atrial ﬁbrillation; VTED: venous thromboembolic disease; S: stroke
thrombosis.A. Steib et al.
4 hours before surgery. The HAS website presents bridging
roposals.
If the eve of surgery INR is greater than 1.5, addition
f 5mg per os vitamin K is recommended. Surgery should
e scheduled for the morning, to optimize postoperative
anagement.
In emergency, with less than 12 hours to surgery, adminis-
ration of 25 IU/kg (= 1ml/kg) iv PPSB (coagulation factors II,
II, IX and X) and 5mg per os vitamin K is recommended, with
ontrol INR 30minutes after injection to check reversion.
Postoperative management is less straightforward,
epending on the previously estimated thrombosis risk. In
igh-risk situations and in absence of major persistent hem-
rrhage risk, resumption of VKA is recommended within
4 hours or at least as soon as possible after surgery.
eparin should be administered at curative dose in the
—48 hours postoperatively. When curative treatment can-
ot be implemented rapidly, antithrombotic prophylaxis is to
e undertaken on the usual protocol. The attitude of spine
urgeons, however, was reported to vary greatly in terms of
he interval to initiation of antithrombotic prophylaxis [14],
hich is generally at 24—48 hours post-surgery, on subjective
riteria of personal experience.
In low thrombosis risk situations, rapid resumption of
KA and initiation of antithrombotic prophylaxis are recom-
ended.
These standardized management protocols are likely to
e brought into question by the advent of new oral anticoag-
lants (dabigatran, rivaroxaban, apixaban, etc.). Their ﬁeld
f action can be extended well beyond their present indica-
ions, for antithrombotic prophylaxis after total hip or knee
eplacement. Large scale trials have been run, particularly
n the cardiovascular ﬁeld (AF, DVT, acute coronary syndrome
ACS]) with a long-term view to replacing VKAs. This strat-
gy would mean revisiting perioperative management as a
hole, as their action time is much shorter (shorter pre-
perative withdrawal?) but their effect much faster (what
ostoperative resumption strategy?).
atient under antiplatelets
ong-course antiplatelets are prescribed to prevent arte-
ial thrombosis. They comprise acetylsalicylic acid (aspirin)
nd thienopyridines (clopidogrel [Plavix®] or ticlopidine
Ticlid®]), prescribed in isolation or in association. While
cting on different speciﬁc targets, their effect is an irre-
ersible 7—10 days inhibition of platelet function.
A) according to indications.
VTED
other patients Other DVT or PE
IS, systemic embolism PE < 3months
Proximal DVT < 3months
Recurrent VTED
; IS: ischemic stroke; PE: pulmonary embolism; DVT: deep venous
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Treatment-termination thrombosis risk depends on the
type of underlying pathology. It is considered major in ACS
of less than 1 month and for bare or active stents implanted
respectively for less than 6 weeks or 1 year [15,16], and
intermediate in secondary prevention of MI, stroke or lower
limb arteriopathy. Several studies have spotlighted preoper-
ative interruption of antiplatelet therapy as an independent
risk factor for perioperative arterial thrombotic accident
(MI, ischemic stroke [IS]) [15].
Current antiplatelet management guidelines therefore
tend to recommend perioperative maintenance if compa-
tible with the surgical procedure and its associated
hemorrhage risk [15—17]. Risk assessment has not been eval-
uated in the spinal surgery literature [18]. A Chinese study of
138 procedures for narrow lumbar canal found signiﬁcantly
elevated bleeding associated with aspirin therapy [19]. A
survey of practice among German neurosurgeons found that
they interrupted antiplatelet therapy for a mean of 7 days
[20].
What proposals can be made in practice, awaiting the
guidelines currently being drawn up by the HAS and due to
be published late 2011 or in 2012? Treatment should be main-
tained in case of low hemorrhage risk. Otherwise, at least
aspirin should be maintained (with the possibility, if not con-
traindicated, of temporary conversion from clopidogrel to
aspirin). Recent bare or active stenting requires delaying
non-emergency surgery to after 6 weeks or 1 year, respec-
tively; this long delay following active stenting means the
cardiologist needs to be informed in advance if surgery is
liable to be scheduled within the year following stenting, in
which case a bare stent may be preferred.
In case of clear per- and postoperative hemorrhage risk
(including risk of maintaining aspirin associated with pos-
sible postoperative antithrombotic prophylaxis), temporary
preoperative interruption is preferable. Five days interrup-
tion is recommended for clopidogrel; for aspirin, it could be
shorter, a recent study having demonstrated platelet func-
tion recovery after 3 days interruption in 58 patients on
long-course treatment with 100mg per day [21].
Non-steroid anti-inﬂammatory (NSAI) or LMWH substi-
tution has not proved its efﬁcacy. Early postoperative
resumption is vital in order to avoid major thrombotic events
(MI, stroke).
In emergency surgery for patients under antiplatelets,
platelet transfusion is indicated in case of hemorrhage. It
is not, however, indicated preventively according to the
French health-products safety agency (Agence franc¸aise de
sécurité sanitaire des produits de santé [Afssaps]). Adju-
vant bleeding control methods (normothermia, correction
of anemia, tranexamic acid, posture, etc.) help limit blood
loss [2,22,23].
The arrival on the market of new antiplatelet agents (pra-
sugrel, ticagrelor) will lead to a review of the management
principles outlined above. They have the advantage of being
more effective against thrombosis (but also on bleeding),
more fast-acting and, in the case of ticagrelor, reversible.
These pharmacologic speciﬁcities will require adapting pre-
and postoperative strategy, as with the new anticoagulants.
In conclusion, perioperative management of drugs
impacting hemostasis requires real case-by-case assessment
of the risk/beneﬁt ratio: on one hand, the hemorrhage
risk entailed by maintaining treatment and, on the other,
[S105
he thrombosis risk entailed by perioperative withdrawal.
ialog between the various physicians (surgeon, anesthesi-
logist, cardiologist) is a prerequisite. The strategy decided
n should be recorded in the patient’s ﬁle.
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